MedTrace Logo

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

NCT04960891 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-01-21

No results posted yet for this study

Summary

This Expanded Access Program aims to:

1. Provide access to tebentafusp for mUM patients.
2. Provide access to tebentafusp for patients, who were on the control arm of the randomized controlled Phase II trial (IMCgp100-202) and were unable to crossover during the specified window.
3. Ensure that patients, who are benefiting from tebentafusp treatment while participating in an ongoing Immunocore sponsored clinical study (e.g., IMCgp100-102 or IMCgp100-201), may continue tebentafusp treatment on this Programme once the ongoing trial has met all of its key primary and secondary objectives.

Conditions

Interventions

DRUG

Tebentafusp

Concentrate solution for intravenous infusion

Sponsors & Collaborators

  • Clinigen, Inc.

    collaborator INDUSTRY

  • Immunocore Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04960891 on ClinicalTrials.gov